
At ASCO 2026, experts discussed balancing the survival benefits of GLP-1 RAs with the nursing challenge of managing cancer-related anorexia.

At ASCO 2026, experts discussed balancing the survival benefits of GLP-1 RAs with the nursing challenge of managing cancer-related anorexia.

Camizestrant switch at ESR1 mutation detection improves PFS, patient-reported outcomes, and delays chemotherapy in advanced breast cancer.

Phase III ROSELLA data shows relacorilant plus nab-paclitaxel improves OS in platinum-resistant ovarian cancer with a manageable safety profile.

HR20013 plus dexamethasone improves delayed emesis control and daily functioning for patients on moderately emetogenic chemotherapy in the phase 3 PROTECT trial.

ASCO 2026 data show GLP-1 RAs reduce HR+/HER2- breast cancer risk and improve overall survival in non-diabetic women with a BMI of 25-35 kg/m².

Oncology nurses play a vital role in managing cognitive and metabolic toxicities during long-term lorlatinib therapy for ALK+ NSCLC.

New ASCENT-04 data shows sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1+ TNBC regardless of Trop-2, BRCA, or HER2 status.

ASCO 2026: Dr. Shubham Pant discusses managing the unique side effect profile of daraxonrasib, a new standard of care for metastatic pancreatic cancer.

ASCO 2026: The EMERALD-3 study shows adding STRIDE with or without lenvatinib to TACE significantly extends PFS for patients with unresectable HCC.

ASCO 2026: Adding ipatasertib to pembrolizumab improved ORR to 41% in first-line R/M HNSCC, significantly outperforming pembrolizumab monotherapy.

A large real-world analysis found that higher frailty scores were associated with increased odds of toxicities, hospitalization, and mortality in patients receiving ADC, BiTE, and CAR T-cell therapies.

A real-world study shows concurrent GLP-1 RA and ICI use may significantly improve long-term survival and lower toxicities for patients with cancer.

Dr. Emily Podany explains how oncology nurses can screen for food insecurity and provide evidence-based solutions to improve patient outcomes.

Dr. Paolo Tarantino highlights the need for drug-specific prophylaxis to manage toxicities like ILD and neutropenia in patients receiving ADCs.

Final KEYNOTE-522 analysis shows 85.1% 7-year OS in early TNBC. Dr. Javier Cortes details nursing management of immune-related side effects.

An updated post hoc analysis showed that imetelstat nearly doubled overall survival compared with best available therapy in patients with JAK inhibitor–relapsed or refractory myelofibrosis.

The phase 2 ARACOG study is the first head-to-head randomized comparison of cognitive effects between the 2 androgen receptor pathway inhibitors.

Learn how prostate cancer treatments affect erections—and the tailored rehab options, from Cialis to pumps and injections, that restore intimacy.

Studies to be presented at the 2026 ASCO Annual Meeting examine GLP-1 receptor agonists in relation to cancer progression, survival, and immune-related adverse events.

Study findings suggest biologic aging and neighborhood deprivation may shape cognitive benefits from exercise after breast cancer.

A study presented at ONS 2026 shows how primary palliative care interventions improve patient-provider relationships and goal-setting in cellular therapy.

Cedars-Sinai used a nursing education framework to shift a 63-bed oncology unit to a progressive care model, improving immunotherapy monitoring.

A quality improvement project at Sylvester Comprehensive Cancer Center shows that structured education enhances nurse triage for treatment toxicities.

Hackensack researchers evaluated an antineoplastic agent onboarding program for nurses treating solid and hematologic tumors.

New data from the ONS Congress suggest that chemotherapy-induced peripheral neuropathy may persist for years in survivors of frontline lymphoma care.

A UAMS study shows non-musical sound machines significantly reduce patient anxiety during gynecology oncology appointments in a cost-effective way.

Both pre- and post-evidence–based practice change occlusion rates were low with relation to anticipated rates among hospitalized adult patients with cancer.

Jill Winther earned the 2026 Extraordinary Healer® Award for her leadership, advocacy and dedication to oncology nursing.

At SGO 2026, the BEHOLD-1 trial revealed a 62% ORR for mocertatug rezetecan in PROC, offering a manageable new ADC option for oncology nurses to track.

1INSPIRE data at SGO 2026 confirms frontline niraparib (Zejula) has a manageable safety profile with low discontinuation rates in ovarian cancer.